Neurological disorders throughout acute SARS-CoV2 infection : A comparative study between vaccinated and non-vaccinated patients
Copyright © 2024 Elsevier B.V. All rights reserved..
BACKGROUND: The role of vaccination on Covid-19 severity in neurological patients is still unknown. We aim at describing clinical characteristics and outcomes of breakthrough and unvaccinated Covid-19 patients hospitalized for neurological disorders.
METHODS: Two hundred thirty-two Covid-19 patients were admitted to a neuro-Covid Unit form March 1st 2021 to February 28th 2022. Out of the total sample, 74 (32%) were full vaccinated. The prevalence, clinical characteristics, disease severity, expressed by Brescia-COVID Respiratory Severity Scale (BCRSS) and National Early Warning Score 2 (NEWS2), and final outcomes of neurological syndromes were compared between vaccinated and unvaccinated cases. Cox regression analysis was implemented in order to investigate the combined effect of predictors of mortality.
RESULTS: Breakthrough vaccinated cases were older (years 72.4 ± 16.3 vs 67.0 ± 18.9 years, p = 0.029), showed higher pre-admission comorbidity score and Clinical Frailty scale score (4.46 ± 1.6 vs 3.75 ± 2.0, p = 0.008) with no differences in terms of disease progression or mortality rate (16.2% vs 15.2%), compared to full-dose vaccinated patients. Cox-regression analysis showed age and NEWS2 score as the variables with a significant relation to mortality between the two groups, independently from pre-morbid conditions and inflammatory response.
CONCLUSION: This study on breakthrough COVID-19 infection could help identify vulnerable neurological patients with higher risk of poor outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:457 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 457(2024) vom: 15. Feb., Seite 122898 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cristillo, Viviana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2024.122898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36771809X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36771809X | ||
| 003 | DE-627 | ||
| 005 | 20240219232023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2024.122898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM36771809X | ||
| 035 | |a (NLM)38281402 | ||
| 035 | |a (PII)S0022-510X(24)00033-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cristillo, Viviana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurological disorders throughout acute SARS-CoV2 infection |b A comparative study between vaccinated and non-vaccinated patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The role of vaccination on Covid-19 severity in neurological patients is still unknown. We aim at describing clinical characteristics and outcomes of breakthrough and unvaccinated Covid-19 patients hospitalized for neurological disorders | ||
| 520 | |a METHODS: Two hundred thirty-two Covid-19 patients were admitted to a neuro-Covid Unit form March 1st 2021 to February 28th 2022. Out of the total sample, 74 (32%) were full vaccinated. The prevalence, clinical characteristics, disease severity, expressed by Brescia-COVID Respiratory Severity Scale (BCRSS) and National Early Warning Score 2 (NEWS2), and final outcomes of neurological syndromes were compared between vaccinated and unvaccinated cases. Cox regression analysis was implemented in order to investigate the combined effect of predictors of mortality | ||
| 520 | |a RESULTS: Breakthrough vaccinated cases were older (years 72.4 ± 16.3 vs 67.0 ± 18.9 years, p = 0.029), showed higher pre-admission comorbidity score and Clinical Frailty scale score (4.46 ± 1.6 vs 3.75 ± 2.0, p = 0.008) with no differences in terms of disease progression or mortality rate (16.2% vs 15.2%), compared to full-dose vaccinated patients. Cox-regression analysis showed age and NEWS2 score as the variables with a significant relation to mortality between the two groups, independently from pre-morbid conditions and inflammatory response | ||
| 520 | |a CONCLUSION: This study on breakthrough COVID-19 infection could help identify vulnerable neurological patients with higher risk of poor outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Neurological disease | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Pilotto, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Piccinelli, Stefano Cotti |e verfasserin |4 aut | |
| 700 | 1 | |a Libri, Ilenia |e verfasserin |4 aut | |
| 700 | 1 | |a Locatelli, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Giunta, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzoleni, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Pezzini, Debora |e verfasserin |4 aut | |
| 700 | 1 | |a Arici, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Gipponi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a di Cola, Francesca Schiano |e verfasserin |4 aut | |
| 700 | 1 | |a Cottini, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Gamba, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Magoni, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Padovani, Alessandro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 457(2024) vom: 15. Feb., Seite 122898 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:457 |g year:2024 |g day:15 |g month:02 |g pages:122898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2024.122898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 457 |j 2024 |b 15 |c 02 |h 122898 | ||